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Alzheimer’s disease (AD) is the most common cause of dementia of late life. AD 
manifests as progressive memory impairment followed by a gradual decline in other 
cognitive abilities. For AD is characteristic the abnormal accumulation or aggregation of 
proteins.  
Advanced glycation endproducts (AGEs) are a heterogenous group of compounds 
that are formed when carbonyl group of reducing sugars reacts by a non-enzymatic 
reaction with amino acids in proteins, lipids and nucleic acids. The formation of AGEs 
promotes the deposition of proteins due to the protease resistant crosslinking, therefore 
is difficult to eliminace them from organism. AGEs can be detected in pathological 
deposits such as amyloid plaques and neurofibrillary tangles, which are prominent 
pathological feature sof AD. The formation of AGEs activate inflammatory signalling 
pathways, which are mediated by their receptor for advanced glycation endproducts 
(RAGE). RAGE is the signal transduction receptor which distinguishes a variety of signalling 
molecules including AGEs, β-amyloid, HMGB1 and etc. Therefore AGEs and and their 
receptor RAGE may play a crucial role in pathogenesis of AD.  
This thesis is a literature review, which aimed to assemble findings targered to 
AGEs and receptor RAGE nad their involvement in the pathogenesis of AD. Since AGEs and 
their harmful effects to human health can cause undesirable diseases, it is necessary to 
investigate these potential therapeutical compounds that  show inhibition effects to AGEs 
and RAGE. Therefore I have focused on compounds both synthetic and natural products, 
which might bet the effective inhibitors of AGEs and their receptor RAGE. In this review , I 
tried to summarize recent advances in the development of novel strategies which slow 
down the progression and treatment of neurodegenerative diseases especially of AD. 
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